ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2284

How Well Do Generic Patient Reported Outcomes Measurement Information System Instruments Capture Health Status In Rheumatoid Arthritis?

Susan J. Bartlett1,2, Ana-Maria Orbai3, Trisha Duncan3 and Clifton O. Bingham III3, 1Clinical Epidemiology, McGill University, Montreal, QC, Canada, 2Division of Rheumatology, Johns Hopkins University, Baltimore, MD, 3Rheumatology, Johns Hopkins University, Baltimore, MD

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Health, measure, patient outcomes, quality of life and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis-Clinical Aspects III: Outcome Measures, Socioeconomy, Screening, Biomarkers in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: PROMIS offers precise, reliable generic measurement of physical, mental and social health across chronic conditions. However, little is known about the validity and performance of PROMIS instruments in rheumatoid arthritis (RA), where high levels of pain and fatigue and low physical function and mood are common.

Methods: Data are from the baseline visit of the first 125 RA patients enrolled in an ongoing study to evaluate systematically integrating patient reported outcomes (PROs) into arthritis care. Patients completed PROMIS computerized adaptive tests (CATs) assessing pain, fatigue, physical function, mood, sleep and social roles/activities using a tablet computer linked to Assessment Center in the waiting room immediately prior to the visit. Legacy measures (100 mm VAS for pain and fatigue, MHAQ) were also obtained as well as traditional clinical indicators of disease activity. PROMIS and legacy measures were compared using Spearman correlations and regression and across CDAI disease activity levels with ANOVA.

Results: Patients were mostly female (79%) and white (86%) with a mean (SD) age of 56 (13) and disease duration of 12 (9) yr; 10% were diagnosed <= 2 yr. PROMIS CATs included an average 63 (12) items requiring 12 (5-32) minutes to complete. PROMIS CATs for pain (intensity, impact), fatigue, physical function, anxiety, depression, anger, sleep (disturbance, impairment) and social roles/activities (participation, satisfaction) correlated highly with pain VAS (r's=.82-.83), fatigue VAS (r=.86) and mHAQ (r=-.74) (p's<.001). A dose-response relationship was evident in PROMIS measures across remission, low and moderate disease activity levels (except anger; see Table). Floor effects were common in legacy measures (16%, 11% and 43% for pain VAS, fatigue VAS and MHAQ, respectively) and were not common in PROMIS instruments.

Conclusion: These data contribute preliminary evidence of convergent and known groups validity and demonstrate robust psychometric performance of PROMIS instruments to assess PROs in people receiving routine RA care. PROMIS CATs can be completed relatively quickly and appear to address some of the well-recognized limitations (non-linearity, floor effects) of existing legacy measures in RA.

 

Estimates of Impact and Mean Values across CDAI Disease Activity Levels on Legacy and PROMIS Measures in Rheumatoid Arthritis.

Variable

B

Effect Size

(β/SE)

Remission

N=33

Low

N=50

Moderate

N=23

High

N=12

Pain 100 mm VAS

18.3

8.0

5.9 ± 7.8a

33.8 ± 25.2b

52.4 ± 28.2c

54.1 ± 26.0c

PROMIS Pain Intensity

4.6

6.6

38.0 ± 7.1a

46.0 ± 6.1b

48.1 ± 7.4b,c

51.7 ± 8.2c

PROMIS Pain Interference

5.6

7.0

45.9 ± 7.7a

55.4 ± 8.5b

58.2 ± 6.2b,c

62.1 ± 8.5c

 

 

 

 

 

 

 

Fatigue 100 mm VAS

18.4

7.1

12.7 ± 17.2a

45.3 ± 29.0b,c

57.5 ± 27.9c*

64.3 ± 21.7c

PROMIS Fatigue

5.7

6.7

46.1 ± 8.5a

55.6 ± 8.8b

59.5 ± 6.9c*

62.3 ± 9.4c

 

 

 

 

 

 

 

mHAQ

.19

5.1

0.1 ± 0.4a

0.3 ± 0.3a

0.5 ± 0.4b

0.7 ± 0.4b

PROMIS Physical Function‡

-5.6

-7.8

50.3± 8.7a

42.7 ± 7.1b

38.2 ± 5.7c

33.7 ± 5.6d**

 

 

 

 

 

 

 

PROMIS Anxiety

2.6

3.6

47.5 ± 7.6a

52.1 ± 8.9b

51.0 ± 8.0a,b

57.4 ± 8.3c

PROMIS Depression

3.0

3.5

46.4 ± 8.5a

49.8 ± 9.3a

50.9 ± 9.4b*

57.1 ± 8.6c*

PROMIS Anger

2.6

2.9

45.2 ± 7.9a

46.8 ± 9.7a

48.9 ± 10.9a

54.2 ± 8.8b

PROMIS Sleep Disturbance

3.2

3.6

46.6 + 9.1a

52.6 + 8.0b

54.3 + 10.2b

55.7 + 8.3c

PROMIS Sleep Impairment

3.8

4.2

46.3 + 9.3a

52.7 + 9.6b

53.7 + 9.1b

58.7 + 6.6c

PROMIS Social† – Participation

-4.7

-5.9

55.2 ± 9.5a

49.9 ± 8.2b

46.7 ± 6.1b

40.1 ± 6.4c

PROMIS Social† – Satisfaction

-5.5

-6.1

55.7 ± 9.6a

47.0 ± 9.6b

44.9 ± 6.6b

38.4 ± 7.1c

†Social Roles and Activities. Differing superscripts denote significantly different groups (p<.05). *p=.06; **p=.08

 


Disclosure:

S. J. Bartlett,
None;

A. M. Orbai,
None;

T. Duncan,
None;

C. O. Bingham III,

PCORI,

2,

OMERACT officer,

6.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/how-well-do-generic-patient-reported-outcomes-measurement-information-system-instruments-capture-health-status-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology